• Users Online: 101
  • Print this page
  • Email this page

  About Us

  About the Journal

The Journal of Immunotherapy and Precision Oncology (JIPO) is a publication of Global Academy of Health Sciences. This is a peer-reviewed online journal with quarterly print on-demand compilation of issues published. The journal allows free access (Open Access) to its contents and permits authors to self-archive a final accepted version of the articles on any OAI-compliant institutional/subject-based repository. 

Aim and Scope
JIPO aims to publish high-quality manuscripts related to the field of immunotherapy and precision oncology. The content will appeal to a broad readership of healthcare professionals and scientists, especially those with an interest in oncology and immunology. There will be innovative original articles including translational science and clinical medicine, review articles, editorials, controversy, and others. Manuscripts related to clinical and translational discoveries related with immunity and cancer and immunotherapy, such as new discoveries about immune system function and biology, new therapeutic approaches to different malignancies, mechanisms of resistance, clinical assessment, and more will be considered for publication. Subjects related to precision oncology including prognostic or predictive markers and innovative targeted therapy advances in diagnostic technology will also be considered. High quality evidence based guidelines of credible professional entities will also be considered for publication. Sub-topic based Supplements may be published. This allows the journal to highlight issues relevant to the Journal readers.

Journal Ethics

Wolters Kluwer and Journal/Association are committed to meeting and upholding standards of ethical behavior at all stages of the publication process. We follow closely the industry associations, such as the Committee on Publication Ethics (COPE), International Committee of Medical Journal Editors (ICMJE) and World Association of Medical Editors (WAME), that set standards and provide guidelines for best practices in order to meet these requirements. For a summary of our specific policies regarding duplicate publication, conflicts of interest, patient consent, etc., please visit www.Medknow.com/EthicalGuidelines.asp

Open Access Publication and Creative Commons Licensing

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Digital Archiving

Wolters Kluwer Medknow provides for long-term digital preservation through two primary partnerships, Portico and CLOCKSS.

Portico is a leading digital preservation service worldwide. The content is preserved as an archival version and is not publically accessible via Portico, but is provided when required under specific conditions, such as discontinuation of the collection or catastrophic failure of the website.

CLOCKSS will enable any library to maintain their own archive of content from Wolters Kluwer Medknow and other publishers, with minimal technical effort and using cheaply available hardware.

Ahead of Print policy

Articles published online under the Ahead of Print model are considered published and can be cited and quoted using the DOI as the reference source. Wolters Kluwer Medknow has a policy that changes will not be made after publication of an article without following accepted procedures for making corrections to the scientific record.

Advertisements

While advertisements are crucial to this journal to be able to keep all content free for everyone, ethical considerations are in place to ensure the integrity of the journal and its content:

  • "Pop-up" and "banner" ads appear on a random, rotating basis. The advertiser has no control or input over the pages where their ads appear.
  • The Editorial Board has full and final approval over the content of all advertisements.
  • Advertisers will never be shown any manuscripts or other content prior to publication.

  Scope of the journal

JIPO aims to publish high-quality manuscripts related to the field of immunotherapy and precision oncology.  The content will appeal to a broad readership of healthcare professionals and scientists, especially those with an interest in oncology and immunology. There will be innovative original articles including translational science and clinical medicine, review articles, editorials, controversy, and others.

Manuscripts related to clinical and translational discoveries related with immunity and cancer and immunotherapy, such as new discoveries about immune system function and biology, new therapeutic approaches to different malignancies, mechanisms of resistance, clinical assessment, and more will be considered for publication. Subjects related to precision oncology including prognostic or predictive markers and innovative targeted therapy advances in diagnostic technology will also be considered.

Sub-topic based Supplements may be published. This allows the journal to highlight issues relevant to the Journal readers. High quality evidence based guidelines of credible professional entities will be considered for publications.

    Medknow Publications   Top
Editorial board